DarioHealth (DRIO) Stock Price

DarioHealth Price

NASDAQ·CLOSED
6.08
​
Market closed

Revenue has compounded at 73.8% per year over the past 11 years to 22.36 M USD. DarioHealth's net margin stands at -186.6%, up from -374.2% several years earlier. Analysts set a median price target of 14.00 USD, implying 130.3% above the current price. Of 11 analysts, 9 rate the stock a buy — an overall Buy consensus.

DarioHealth stock price

Access this data via the Eulerpool API

DarioHealth business model & stock analysis

DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. The company is headquartered in New York City, New York and currently employs 62 full-time employees. The company went IPO on 2013-03-08. DarioHealth operates at the intersection of life sciences, behavioral science, and software technology to deliver integrated and engaging digital therapeutics interventions. The DTx products are centered around its users and include the Dario Blood Glucose Monitoring System and the Dario Smart Diabetes Management Solution, which are provided to its users in the form of a smartphone application that enables the delivery of content and periodical evidence-based reports; the DarioEngage platform, which provides support and two-way real-time connectivity between its users and their caregivers, and Dario Intelligence, which utilizes user data and is an analytics tool that can assist healthcare providers in the treatments and predictability of diseases. The Company’s services are available direct to consumers via online marketplaces including Amazon, Walmart, Best Buy and the Google and Apple app stores.

Frequently asked questions about DarioHealth

Analysts currently set an average price target of 12.50 USD for the DarioHealth stock (median: 14.00 USD), implying +105.6 % versus the latest price. The consensus is based on 11 analyst ratings.

11 analysts currently rate the DarioHealth stock: 9 recommend buying, 2 holding and 0 selling. For 2026, analysts expect DarioHealth to generate revenue of 21.71 M USD and earnings per share of -0.54 USD.

Converted at the current exchange rate, the DarioHealth share trades at 5.43 EUR (6.08 USD).

The DarioHealth share (DRIO) is listed on 1 stock exchanges, including: NASDAQ (DRIO).

The expected revenue of DarioHealth is 21.71 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of DarioHealth is -26.88 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of DarioHealth is currently -11.23. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the DarioHealth stock.

The price-to-sales ratio (P/S) of DarioHealth is currently 13.90. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the DarioHealth stock.

The Eulerpool Quality Score for DarioHealth is 3/10.

The ISIN of DarioHealth is US23725P3082. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of DarioHealth is A2PU1R. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of DarioHealth is DRIO. The ticker symbol is used to trade DarioHealth shares on the stock exchange.

Fair ValueTerminal
6.32 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
139,743.75 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website mydario.com
Currency
USD
Initial public offering
Mar 8, 2013
ISIN
US23725P3082
Cusip
23725P209
Sedol
BL0MJ94
Market capitalization
41.10 M USDMicro Cap
52-Week Range
PEG
0.33
P/E ratio
P/Ee 2026
-11.23
P/Ee 2027
-17.71
P/Ee 2028
-26.73
P/Ee 2029
-28.07
P/Ee 2030
-38.15
P/Se
13.90
EV/EBIT
—
P/B Ratio
0.61
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-41.85 %
Last updated Oct 8, 2026, 3:32 PM

All fundamentals and in-depth analysis of DarioHealth

Our stock analysis for DarioHealth stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of DarioHealth. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.